Search
Search Constraints
You searched for: Author/Creator Perez-Vilar, SilviaLimit your search
- Perez-Vilar, Silvia [remove] 11
- 615.372 9
- Vaccines -- Periodicals 9
- 616.9 2
- Communicable diseases -- Periodicals 2
- Post-marketing surveillance -- Vaccine safety -- Global Vaccine Safety Initiative (GVSI) -- Adverse events following immunization (AEFI) 2
- 4CMenB vaccine -- Meningococcal vaccines -- Neisseria meningitidis serogroup B -- Pharmacovigilance -- Vaccine Adverse Event Reporting System 1
- ADEM Acute disseminated encephalomyelitis -- AEs Adverse events -- ACIP Advisory Committee on Immunization Practices -- CDC Centers for Disease Control and Prevention -- EBGM Empirical Bayes Geometric Mean -- GBS Guillain-Barré syndrome -- ITP Immune thrombocytopenia -- IND Investigational new drug -- IQR Interquartile range -- ISR Injection site reaction -- MRI Magnetic resonance imaging -- MedDRA Medical Dictionary for Regulatory Activities -- MenACWY Meningococcal serogroups A, C, W, and Y -- MS Multiple sclerosis -- MenB-4C Four-component Neisseria meningitidis serogroup B vaccine -- MGPS Multi-Item Gamma Poisson Shrinker -- PTs Preferred Terms -- FDA U.S. Food and Drug Administration -- VAERS Vaccine Adverse Event Reporting System -- HPV Human papillomavirus 1
- AE adverse event -- BSA body surface area -- CDC Centers for Disease Control and Prevention -- DTaP combined diphtheria, tetanus, and acellular pertussis vaccine -- EM erythema multiforme -- FDA Food and Drug Administration -- IIV trivalent inactivated influenza vaccine -- MGPS Multi-Item Gamma Poisson Shrinker -- MedDRA Medical Dictionary for Regulatory Activities -- MMR combined measles, mumps and rubella vaccine -- NDMA N-methyl-D-aspartate -- NSAID non-steroidal anti-inflammatory drug -- PNC7 7-valent conjugated pneumococcal vaccine -- PT Preferred Term -- SJS Stevens Johnson Syndrome -- TEN toxic epidermal necrolysis -- VAERS Vaccine Adverse Event Reporting System 1
- AEFI adverse events following immunization -- AM aseptic meningitis -- CI Confidence Interval -- CSF cerebrospinal fluid -- EMC Erasmus Medical Center -- FDA Food and Drug Administration -- GVSI Global Vaccine Safety Initiative -- ITP immune thrombocytopenic purpura -- IRR incidence rate ratio -- LMICs low and middle-income countries -- MMR measles, mumps, rubella vaccines -- PMNs polymorphonuclear leukocytes -- OR odds ratio -- SCCS self-controlled case series -- SCRI self-controlled risk interval -- WHO World Health Organization 1
- AEFI adverse events following immunization -- AM aseptic meningitis -- CRF case report form -- GVSI Global Vaccine Safety Initiative -- ITP immune thrombocytopenic purpura -- ERC Ethical Review Committee -- GBS Guillain-Barre Syndrome -- IRB Institutional Review Board -- LMICs low and middle-income countries -- PPV positive predictive value -- QAC quality assurance committee -- SCCS self-controlled case series -- WHO World Health Organization 1